Concord Biotech Share Price Gains as Board Approves 1:1 Bonus Share Issue

Concord Biotech Limited recently held a board meeting on September 23, 2026, where key decisions were made regarding the company's capital structure.  

As per the exchange filings, the board approved a bonus share issuance and an increase in authorised capital, reflecting a strategic move to enhance shareholder value. 

Concord Biotech’s Bonus Share Issuance Details 

The board sanctioned a bonus share issuance in a 1:1 ratio, granting shareholders 1 fully paid equity share of ₹1 for every existing share held.  

This issuance will be executed by capitalising the company's share premium account, with a total issuance size of approximately 10,46,16,204 equity shares, amounting to ₹10.46 crore. 

Also Check: Pharmaceuticals Stocks

Authorised Capital Expansion 

To accommodate the bonus issuance, Concord Biotech proposed increasing its authorised share capital from ₹11 crore to ₹22 crore.  

The new capital structure will consist of 22,00,00,000 equity shares of ₹1 each. This change necessitates an amendment to Clause V of the Memorandum of Association, pending shareholder approval. 

Financial Implications and Timeline 

Prior to the bonus issue, the paid-up share capital was ₹10.46 crore. Post-bonus, it will rise to ₹20.92 crore, divided into 20,92,32,408 equity shares.  

The audited share premium available for capitalisation was ₹81.97 crore as of March 31, 2026. The bonus shares are likely to be credited within 2 months from the date of the Board Meeting approving the Bonus, i.e. by November 22, 2026. 

Read More: ZF Commercial Vehicle Control Systems Allots Bonus Shares in 5:1 Ratio to Shareholders Recorded on June 24, 2026! 

Concord Biotech Share Price Performance 

As of September 24, 2026, at 9:22 AM, Concord Biotech share price on NSE was trading at ₹1,560.30, up by 1.82% from the previous closing price. 

Conclusion 

Concord Biotech's board meeting on September 23, 2026, resulted in the approval of a 1:1 bonus share issue and an increase in authorised capital from ₹11 crore to ₹22 crore. The post-bonus paid-up share capital will be ₹20.92 crore, with the issuance executed by capitalising the share premium account. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Looking to invest? Open a Demat Account with Angel One and start trading seamlessly.